The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer
Abstract
PURPOSE: To evaluate the dose, toxicity, and efficacy of paclitaxel in combination with ifosfamide and cisplatin as salvage therapy for patients with relapsed testicular germ cell tumors (GCTs). PATIENTS AND METHODS: Thirty patients with previously treated GCTs were treated with paclitaxel and ifosfamide plus cisplatin (TIP) as second-line therapy. All had favorable prognostic features for response (testis primary tumor site and prior complete response to first-line chemotherapy program). Four cycles of paclitaxel, ifosfamide 5 g/m 2, and cisplatin 100 mg/m 2 were given 21 days apart with granulocyte colony-stimulating factor support, followed by resection of radiographic residua. The dose of paclitaxel was increased among cohorts with dose levels of 175, 215, and 250 mg/m 2; the largest dose was selected for the phase II part of the trial. RESULTS: Twenty-three (77%) of 30 patients achieved a complete response to chemotherapy alone, and one patient achieved a durable partial response with normal tumor markers. Therefore, 24 (80%) achieved a favorable response. Eleven patients with normalized markers after chemotherapy underwent resection of residual tissue, with only necrosis found in 10 and mature teratoma in one. Two patients relapsed, and 22 (73%) of the favorable responses remain durable at a median follow-up duration of 33 months. Myelosuppression was the major toxicity, and two patients had grade 3 neurotoxicity. CONCLUSION: Four cycles of TIP was associated with a high proportion of patients who achieved a complete response, a lack of relapse, and relative tolerability as an ifosfamide-containing salvage regimen for testicular GCTs. The high durable complete response proportion emphasizes the importance of patient selection according to prognostic factors for a favorable outcome to conventional-dose salvage therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Williams, S. D., Birch, R., Einhorn, L. H., Irwin, L., Greco, F. A., & Loehrer, P. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162302 · Cited by 1,170
Bosl, G. J., & Motzer, R. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370406 · Cited by 891
Self-citationChou, T.-C., Motzer, R. J., Tong, Y., & Bosl, G. J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.20.1517 · Cited by 524
Self-citationVinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.
Loehrer, P. J., Gonin, R., Nichols, C. R., Weathers, T., & Einhorn, L. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2500 · Cited by 397
Bajorin, D. F., Sarosdy, M. F., Pfister, D. G., Mazumdar, M., Motzer, R. J., Scher, H. I., Geller, N. L., Fair, W. R., Herr, H., & Sogani, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.598 · Cited by 354
Self-citationLate relapse of testicular cancer.
Baniel, J., Foster, R. S., Gonin, R., Messemer, J. E., Donohue, J. P., & Einhorn, L. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1170 · Cited by 331
Beyer, J., Schwella, N., Zingsem, J., Strohscheer, I., Schwaner, I., Oettle, H., Serke, S., Huhn, D., & Stieger, W. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1328 · Cited by 269
Surgical salvage of chemorefractory germ cell tumors.
Murphy, B. R., Breeden, E. S., Donohue, J. P., Messemer, J., Walsh, W., Roth, B. J., & Einhorn, L. H. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.2.324 · Cited by 198
VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.
Bosl, G. J., Gluckman, R., Geller, N. L., Golbey, R. B., Whitmore, W. F., Herr, H., Sogani, P., Morse, M., Martini, N., & Bains, M. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1493 · Cited by 198
Self-citationMotzer, R. J., Mazumdar, M., Sheinfeld, J., Bajorin, D. F., Macapinlac, H. A., Bains, M., Reich, L., Flombaum, C., Mariani, T., Tong, W. P., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1173 · Cited by 189
Self-citation
Cited by
Pedrazzoli, P., Ledermann, J. A., Lotz, J.-P., Leyvraz, S., Aglietta, M., Rosti, G., Champion, K. M., Secondino, S., Selle, F., Ketterer, N., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl044 · Cited by 655
Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Cavallin-Ståhl, E., et al. (2008) · European Urology · doi:10.1016/j.eururo.2007.12.024 · Cited by 617
Schmoll, H. J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., Fossa, S. D., Skakkebaek, N. E., de Wit, R., Fizazi, K., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh301 · Cited by 510
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067749 · Cited by 496
Kondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., Bosl, G. J., & Motzer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.638 · Cited by 418
Self-citation
Metadata
- Authors
- Motzer, R. J., Sheinfeld, J., Mazumdar, M., Bains, M., Mariani, T., Bacik, J., Bajorin, D., & Bosl, G. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-06-12
- Volume
- 18
- Issue
- 12
- Pages
- 2413-2418
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1748674096
- Cited by
- 253
- References
- 14
- FWCI
- 11.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer. https://app.cochat.ai/papers/10.1200/jco.2000.18.12.2413
- The paper
- Motzer, R. J., Sheinfeld, J., Mazumdar, M., Bains, M., Mariani, T., Bacik, J., Bajorin, D., & Bosl, G. J. (2000). Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.12.2413
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.